Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Clemens

Showing results (31-40 of 395) with videos related to

Pageof 40
Sort By:
International Journal of Cancer|February 7, 1997
Differences in the pharmacokinetics of 13-cis retinoic acid in cancer patientsA R Waladkhani, M R Clemens
International Journal of Molecular Medicine|December 16, 1998
Effect of dietary phytochemicals on cancer development (review)A R Waladkhani, M R Clemens
Journal of Neuromuscular Diseases|November 13, 2023
Reply to F. Muntoni et al.: "In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular DystrophyPaula R Clemens, Eric P Hoffman
Annals of Neurology|May 5, 2021
Concerns Regarding Therapeutic Implications of Very Low-Level DystrophinEric P Hoffman, Paula R Clemens
Der Internist|September 1, 1989
[Genetic defects as causes of anemia]M R Clemens, H D Waller
Nephron|January 1, 1989
Lipid abnormalities and peroxidation of erythrocytes in nephrotic syndromeM R Clemens, Z Bursa-Zanetti
Biochemistry|November 24, 1992
Locations of contacts between individual zinc fingers of Xenopus laevis transcription factor IIIA and the internal control region of a 5S RNA geneJ J Hayes, K R Clemens
European Neurology|January 1, 1994
Gene therapy prospects for Duchenne muscular dystrophyP R Clemens, C T Caskey
Current Neurology and Neuroscience Reports|March 20, 2002
Progress in gene therapy for Duchenne muscular dystrophyP R Clemens, F J Duncan
Current Opinion in Neurology|September 4, 2012
Pharmacological therapies for muscular dystrophiesHoda Abdel-Hamid, Paula R Clemens
Pageof 40

Showing results (31-40 of 395) with videos related to

Sort By:
Pageof 40
International Journal of Cancer|February 7, 1997
Differences in the pharmacokinetics of 13-cis retinoic acid in cancer patientsA R Waladkhani, M R Clemens
International Journal of Molecular Medicine|December 16, 1998
Effect of dietary phytochemicals on cancer development (review)A R Waladkhani, M R Clemens
Journal of Neuromuscular Diseases|November 13, 2023
Reply to F. Muntoni et al.: "In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular DystrophyPaula R Clemens, Eric P Hoffman
Annals of Neurology|May 5, 2021
Concerns Regarding Therapeutic Implications of Very Low-Level DystrophinEric P Hoffman, Paula R Clemens
Der Internist|September 1, 1989
[Genetic defects as causes of anemia]M R Clemens, H D Waller
Nephron|January 1, 1989
Lipid abnormalities and peroxidation of erythrocytes in nephrotic syndromeM R Clemens, Z Bursa-Zanetti
Biochemistry|November 24, 1992
Locations of contacts between individual zinc fingers of Xenopus laevis transcription factor IIIA and the internal control region of a 5S RNA geneJ J Hayes, K R Clemens
European Neurology|January 1, 1994
Gene therapy prospects for Duchenne muscular dystrophyP R Clemens, C T Caskey
Current Neurology and Neuroscience Reports|March 20, 2002
Progress in gene therapy for Duchenne muscular dystrophyP R Clemens, F J Duncan
Current Opinion in Neurology|September 4, 2012
Pharmacological therapies for muscular dystrophiesHoda Abdel-Hamid, Paula R Clemens
Pageof 40